$0.45 0.00 (0.53%) Galena Biopharma Inc - NASDAQ

Jul. 25, 2016 | 04:00 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 0.45
Trade Time: Jul 25 04:00 PM Eastern Daylight Time
Change: +0.00 (0.53%)
Prev Close: 0.45
Open: 0.47
Bid: 0.45
Ask: 0.45
  1. No results found.
  1. Galena Biopharma 2016 Outlook Focuses On 'High Value' Cancer Immunotherapy Pipeline

    Benzinga | Jan. 13, 2016 | 13:37PM EST
  2. Mid-Afternoon Market Update: Dow Tumbles Over 300 Points; Uniqure Shares Gain Following Release Of Clinical Trial Data

    Benzinga | Jan. 7, 2016 | 15:02PM EST
  3. Mid-Day Market Update: Finish Line Drops On Weak Results; Dynavax Shares Spike Higher

    Benzinga | Jan. 7, 2016 | 12:03PM EST
  4. Shares Of Galena Biopharma Plunged On Thursday, Company Announces Public Offering

    Benzinga | Jan. 7, 2016 | 10:43AM EST
  5. Mid-Morning Market Update: Markets Open Lower; KB Home Misses Q4 Views

    Benzinga | Jan. 7, 2016 | 09:54AM EST
  6. Midatech Completes Acquisition of Zuplenz from Galena Biopharma

    Benzinga | Dec. 30, 2015 | 04:20AM EST
  7. Midatech Agrees to Acquire Zuplenz from Galena Biopharma for $3.75M Plus Up to $26M in Milestone Payments

    Benzinga | Dec. 18, 2015 | 04:19AM EST
  8. Benzinga's Top Upgrades

    Benzinga | Nov. 12, 2015 | 09:30AM EST
  9. Galena Biopharma Presents GALE-302 Preliminary Immunologic Data Optimizing GALE-301 at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting

    Benzinga | Nov. 9, 2015 | 07:17AM EST
  10. Galena Biopharma Collaborates With the National Cancer Institute on a Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Ductal Carcinoma in Situ Patients

    Benzinga | Sep. 30, 2015 | 07:06AM EST
  11. Galena Biopharma Launches Zuplenz Oral Soluble Film

    Benzinga | Jul. 29, 2015 | 07:06AM EST
  12. Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Phase 2 Data at the European Hematology Association 20th Congress

    Benzinga | Jun. 15, 2015 | 07:06AM EST
  13. Monday Morning Movers: Achillion Up, Regulus Down Following Drug Results

    Benzinga | Feb. 9, 2015 | 09:05AM EST
  14. Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data At The 56th American Society of

    Benzinga | Dec. 8, 2014 | 07:08AM EST
  15. UPDATE: MLV & Co Reiterates On Galena Biopharma As External Risks Have Subsided

    Benzinga | Nov. 20, 2014 | 10:05AM EST
Trading Center